AI assistant
Oramed Pharmaceuticals Inc. — Director's Dealing 2023
Jan 4, 2023
6965_rns_2023-01-04_317fe848-d31a-4d36-a149-a95758406350.pdf
Director's Dealing
Open in viewerOpens in your device viewer
FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
Check this box if no longer subject to Section 16. Form 4 or
Instruction 1(b).
Form 5 obligations may continue. See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
| 1. Name and Address of Reporting Person Rabinowitz Michael |
2. Issuer Name and Ticker or Trading Symbol Oramed Pharmaceuticals Inc. [ORMP] |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _ Director _ 10% Owner |
|||
|---|---|---|---|---|---|
| (Last) (First) (Middle) 1185 Avenue of the Americas |
3. Date of Earliest Transaction (Month/Day/Year) 01/03/2023 |
Officer (give title below)____ Other (specify below) X Chief Commercial Officer |
|||
| (Street) New York NY 10036 (City) (State) (Zip) |
4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
| 1.Title of Security (Instr. 3) |
2. Transaction 2A. Deemed Date Execution Date, if (Month/Day/Year) any |
3. Transaction Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) |
6. Ownership Form: |
7. Nature of Indirect Beneficial |
||||
|---|---|---|---|---|---|---|---|---|---|---|
| (Month/Day/Year) | Code | V | Amount | (A) or (D) |
Price | (Instr. 3 and 4) | Direct (D) or Indirect (I) (Instr. 4) |
Ownership (Instr. 4) |
||
| Common Stock | (1) 01/03/2023 |
S | 1,425 | D | \$13.0132 | 138,043 | D | |||
| Common Stock | (1) 01/03/2023 |
S | 11,900 | D | \$12.4917 (2) |
126,143 | D |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
| 1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | 8. Price of | 9. Number of | 10. | 11. Nature | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Derivative | Conversion | Date | Execution Date, if | Transaction | 5. Number of |
6. Date Exercisable and Expiration Date |
7. Title and Amount of |
Derivative | Derivative | Ownership | of Indirect | ||||
| Security | or Exercise | (Month/Day/Year) | any | Code | Derivative | (Month/Day/Year) | Underlying | Security | Securities | Form of | Beneficial | ||||
| (Instr. 3) | Price of | (Month/Day/Year) | (Instr. 8) | Securities | Securities | (Instr. 5) | Beneficially | Derivative | Ownership | ||||||
| Derivative | Acquired | (Instr. 3 and 4) | Owned | Security: | (Instr. 4) | ||||||||||
| Security | (A) or | Following | Direct (D) | ||||||||||||
| Disposed of | Reported | or Indirect | |||||||||||||
| (D) | Transaction(s) | (I) | |||||||||||||
| (Instr. 3, 4, | (Instr. 4) | (Instr. 4) | |||||||||||||
| and 5) | |||||||||||||||
| Amount | |||||||||||||||
| or | |||||||||||||||
| Date | Expiration | Number | |||||||||||||
| Code | V | (A) | (D) | Exercisable | Date | Title | of Shares |
Explanation of Responses:
(1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.
(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$12.01 to \$13.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.
/s/ Michael Rabinowitz 01/04/2023
**Signature of Reporting Person Date
* If the form is filed by more than one reporting person, see Instruction 4(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.